OncoSec Medical Inc (ONCSQ)

[hschlauch]

Does anyone else find it bizarre that there hasn't been much discussion on preclinical developments? We have some notion of what the next product will contain - a combination of encoded genes delivered intratumorally via EP - but in what indication(s)? We haven't seen any preclinical data for quite some time. Sounds like it will be used with their new TRACE technology, but that is about all we know.

Could they also be aggressively pursuing a program for electrogene transferred monoclonal antibodies, i. e. checkpoint inhibitors, which were the subject of a recent worldwide patent application? I had mentioned this before and I will repeat again here, if they are seriously pursuing the development of gene encoded monoclonal antibodies that can be delivered and expressed either intratumorally or systemically (intramuscular EP) - and to be used with their new TRACE technology - then I think everyone will be in for quite a surprise. I think Kevin Hollevoet's presentation at the investor and analyst day on November 17 was more meaningful than people realize.